BRIEF-Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase

Reuters Staff

1 Min Read

Feb 13 (Reuters) - ERYTECH PHARMA SA:

* ‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE

* ‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

BRIEF-Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​

BRIEF-Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase